Biosimilární enoxaparin v prevenci a léčbě tromboembolické nemoci
| Title in English | Biosimilar enoxaparin in the prevention and treatment of thromboembolic disease |
|---|---|
| Authors | |
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| web | https://farmakoterapeutickarevue.cz/ |
| Keywords | enoxaparin; biosimilar; equivalence; interchangeability; extrapolation; thromboembolic disease |
| Description | Low-molecular-weight heparins and specifically enoxaparin are used in a number of indications. The most common is undoubtedly the prevention and treatment of thromboembolic disease. Since 2020, biosimilar enoxaparin has been available on the Czech market alongside the original product. Its indications, posology and other aspects completely reflect the original. The aim of this article is to explain the principles of extrapolation, summarize data on the specific biosimilar enoxaparin available in the Czech Republic and data available on other similar molecules in the world. It also aims to highlight some modalities of the safe use of biosimilar enoxaparin in routine clinical practice. |
| Related projects: |